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Disease Questionnaire (IBDQ)]. Over the years a standardized document was de-
veloped to help the authors to clarify the concepts and intent of each item of their
questionnaire(s). This document and examples will be presented. CONCLUSIONS:
This review demonstrates the lack of a formal, written concept lists for PRO ques-
tionnaires developed before the publication of the FDA guidance and the need to
develop standardized documents. Involvement of the developer(s) is crucial at this
step.
Research on Methods – Statistical Methods
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NONPARAMETRIC ESTIMATION OF INCREMENTAL COST EFFECTIVENESS
RATIO ACCOUNTING FOR SKEWNESS
Blough DK
University of Washington, Seattle, WA, USA
OBJECTIVES: Typically, mean costs and mean measures of effectiveness are used
in the estimation of the incremental cost effectiveness ratio (ICER). Cost and effec-
tiveness distributions, however, are often skewed. The goal of this work is to use a
nonparametric generalization of location to obtain a location region in the cost
effectiveness plane. The region accounts for uncertainty and all points in the re-
gion are appropriate estimates of the ICER that account for skewness in the mar-
ginal distributions.METHODS: First, analogous toMann-Whitney, all pairwise cost
and effectiveness treatment differences are computed. Using univariate methods,
an estimate of a location rectangle is obtained as the Cartesian product ofmarginal
location intervals, intervals that account for skewness. By considering the inter-
section of such rectangles over all orthogonal transformations, a closed convex
region is obtained. This method will then be applied to simulated bivariate cost
effectiveness data using both symmetric and skewed distributions. Kolmogorov-
Smirnov provides simultaneous confidence bands for each univariate rectangle.
Any point of this region is an estimate of the ICER; all such points satisfy basic
axioms of bivariate location. This approach will also be used to construct a gener-
alization of the cost effectiveness acceptability curve with uncertainty incorpo-
rated. A test for marginal skewness can precede the construction of the location
region. RESULTS: By comparing the location region with the usual bootstrap esti-
mates for the ICER, it was found that the location region approach produced con-
fidence intervals that were considerably larger for both skewed and symmetric
distributions of costs and effectiveness. CONCLUSIONS: This work provides esti-
mates of the ICER that appropriately accounting for skewness. In such cases, the
mean is not the best measure of location. In spite of the used of the nonparametric
bootstrap to obtain confidence intervals, skewness introduces an extra element of
variability that should be accounted for.
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THE DISCRETE MODELLING OF INTERVENTIONS WITH CONTINUOUSLY
VARYING COSTS AND EFFECTS: IMPLICATIONS FOR ICERS, CEACS AND EVPI
O’Mahony J, van Rosmalen J
Erasmus University Medical Center, Rotterdam, The Netherlands
OBJECTIVES: To show how the discrete modelling of continuously varying dose-
response relationships in cost-effective analysis (CEA) influences incremental
cost-effectiveness ratios (ICERs), cost-effectiveness acceptability curves (CEACs)
and the expected value of perfect information (EVPI). In particular, to show that
each of these metrics is contingent on the discrete comparisons chosen within a
CEA.METHODS: The cost-effectiveness of a hypothetical intervention with a con-
tinuous dose-response relationship is simulated. The cost-effectiveness of a small
number of possible dose levels is simulated first. The analysis is then repeated a
number of times, progressively increasing the number of possible doses and result-
ing combinations of costs and effects. For each run of the analysis ICERs are calcu-
lated for each dose level, a probabilistic sensitivity analysis is simulated, and
CEACs and the EVPI are plotted. RESULTS: As the number of potential cost and
effect combinations increases, the ICERs for each dose level increase, the CEACs fall
towards zero and the EVPI both rises and changes from having sharp inflection
points to being a smooth, downward-sloping curve. CONCLUSIONS: Many inter-
ventions demonstrate dose-response relationships, most of which are in principle
continuous, even if doses are typically varied discretely. The continuously increas-
ing intensity of interventionsmeans the number of possible alternatives is infinite.
The general conclusion from the analysis is that each of themetrics presented here
are contingent on the discrete comparisons chosenwithin the analysis. The signif-
icance of this finding for CEACs depends on their interpretation,which varies in the
literature. The significance for EVPI is that while it has previously been recognised
that excluding relevant comparators can reduce the EVPI, including all theoreti-
cally relevant alternatives may be impossible. Further work may be required to
understand this constraint on measuring the upper bound of the value of further
research.
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THE EXTENSION OF THE COST-EFFECTIVENESS ACCEPTABILITY CURVE: HOW
TO MAKE IT MORE INFORMATIVE?
Kamae I1, Araki D2, Kamae M3
1Keio University Graduate School of Health Management, Fujisawa, Japan, 2Meiji University of
Integrative Medicine School of Nursing Science, Nantan-shi, Kyoto, Japan, 3Tufts Medical Center,
Boston, MA, USA
OBJECTIVES: To develop new schemes which can make the cost-effectiveness ac-
ceptability curve (CEAC) augmented to be more informative regarding the types of
acceptance and statistical inference.METHODS:Theoretical approaches have been
undertaken to address two questions: how the area under the curve (AUC) can be
zoned by the types of acceptance, and how the accepted dataset of incremental
cost-effectiveness ratios (ICERs), which are generated by computer runs, can be
statistically associated with a standard threshold of ICER. RESULTS: The AUC of a
typical sigmoid-shaped CEAC was divided into three zones, each of which repre-
sents the proportion, pi  ni / n(0), where ni is the number of plots on the cost-
effectiveness plain belonging to the quadrant i (i1:South-East, 2:North-East and
3:South-West), and n(0) is the total number of plots (i.e., n(0)n1n2n3) ac-
cepted for the threshold, 0, of ICER. A solution for the second question was “a new
CEAC of themean (MCEAC)”, which can be constructed by plotting a pair of m0 and
p0 instead of a pair of 0 and p0, where 0: the threshold of ICER for acceptance, p0:
the probability of acceptance for the threshold 0, and m0: the mean ICER of all the
plots accepted for the threshold 0. Also, statistical validity of the MCEAC was
inferred by the confidence interval of the mean m0 using t-test. Furthermore, the
series of confidence intervals defined for one threshold 0 corresponding to differ-
ent size of computer runs were summarized as a diagram for showing the progres-
sion of the confidence intervals, which looks similar to the forest plot in meta-
analysis. All those schemes were graphically illustrated based on examples.
CONCLUSIONS: Visualizing the component types of acceptance in the AUC, draw-
ing theMCEAC, and the progression diagramof confidence intervalswill provide us
with more useful information on cost-effectiveness decisions.
Research on Methods – Study Design
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LITERATURE REVIEW OF RANDOMIZED, CONTROLLED STUDIES OF THE
IMPACT OF PHARMACISTS’ INTERVENTIONS TO IMPROVE PATIENT OUTCOMES
Kharat AA1, Borrego M1, Raisch DW2
1University of New Mexico, Albuquerque, NM, USA, 2University of New Mexico College of
Pharmacy, Albuquerque, NM, USA
OBJECTIVES:The objectivewas to summarize the impact of pharmacists’ interven-
tions on patient outcomes as reported in studies utilizing a randomized controlled
trial (RCT) design. METHODS: A comprehensive literature search was conducted
utilizing PubMed and International Pharmaceutical Abstracts for the years 1979-
2009. Studies were included if they evaluated pharmacist-provided interventions,
utilized RCT designs with control groups, andwere conducted in the United States.
Studies were summarized by 1) publication year; 2) study setting; 3) disease/health
condition; and 4) type of intervention provided and whether performed by a phar-
macist alone or a pharmacist with other health care professionals, 5) primary out-
come variables and 6) study findings. Patient outcome results were categorized as
‘positive’, if they found a statistically significant improvement in the patient out-
comes when compared to the control group, or ‘no difference’ if no significant
difference was found. RESULTS: Of the 552 citations reviewed, 100 studies met the
inclusion criteria. The numbers of pharmacists’ intervention studies conducted
using RCT designs increased from 1979 to 2009, with 64% conducted after 2000. The
majority of the studies were conducted in clinic setting (65%) followed by commu-
nity pharmacies (19%), hospitals (12%), home-care (2%), andmultiple settings (2%).
Chronic conditions were studied in 56% of the studies. Studies of interventions
delivered by pharmacists alone comprised 64%, while 36% involved pharmacists
workingwith other health care providers. Overall, ’positive’ patient outcomeswere
demonstrated in 73% of the studies. When interventions were delivered by phar-
macists working with other health care providers, however, 97.2% had positive
outcomes. CONCLUSIONS: ‘Positive’ patient outcomes were demonstrated in the
majority of the studies, supporting increased pharmacists’ roles in the health care
system to improve patient outcomes. When working alongside other health care
providers, the positive impact was most likely.
Research on Methods – Conceptual Papers
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ISSUES CONCERNING THE TRANSLATION OF THE WORD ‘HASSLED’ IN THE
MORISKY MEDICATION ADHERENCE SCALE (MMAS-8)
Griffin A1, Wild D1, Morisky DE2
1Oxford Outcomes Ltd., Oxford, Oxfordshire, UK, 2UCLA School of Public Health, Los Angeles, CA,
USA
OBJECTIVES: The word ‘hassle’ is commonly used in PRO measures including the
Morisky Medication Adherence Scale (MMAS-8). The translation of the word ‘has-
sle’ is used as an example of how creation of a concept elaboration and a full
translation and linguistic validation process can result in a translation that is con-
ceptually equivalent to the source text and to aid in the future translation of am-
biguouswords.METHODS:TheMMAS-8was translated into 29 languages using the
standard methodology of two forward translations, reconciliation, two back trans-
lations, back-translation review, developer review and proofreading. Examples of
translation issues of the word ‘hassled’ in the following statement were assessed:
Do you ever feel hassled about sticking to your anti-rejection treatment plan?
RESULTS: A ‘hassle’ is defined in the Oxford English Dictionary as an ‘irritating
inconvenience’. In the above question, this word encompasses several concepts –
bothered, troubled, disturbed – which were provided to translators in a concept
elaboration document. The translation process resulted in the following: The initial
French translation was back-translated as bothered/annoyed. Alternatives back-
translating as ‘preoccupied’ and ‘inconvenient’ were suggested but rejected. The
developer piloted the final suggestion, debordé (overwhelmed), with French-
speaking students, who agreed that this was the best translation in this context.
For other languages, ‘hassled’ was translated variously as: a nuisance, cumber-
some, difficult, bothersome, troubling, tiresome, irksome, burdensome and com-
plicated. These were queried with translator and the developer to confirm concep-
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tual equivalence to ‘hassled’. CONCLUSIONS: Though not always possible to
translate an English word exactly into the target language, a full translation and
linguistic validation process, including creation of a concept elaboration document
followed by an in-depth discussion at back-translation review stage, enables a
conceptually equivalent translation to be found. The concept elaboration docu-
ment should, where possible, be created in conjunction with the instrument de-
veloper.
PRM41
IS IT TIME TO ELIMINATE THE ICER? USING NET BENEFITS TO REPORT THE
RESULTS OF DETERMINISTIC COST-EFFECTIVENESS ANALYSES
O’Day K, McLaughlin T, Bramley T
Xcenda, LLC., Palm Harbor, FL, USA
BACKGROUND: Incremental cost-effectiveness ratios (ICERs) are used to report the
results of cost-effectiveness (CE) analyses and represent the cost per unit of effec-
tiveness of a more costly and more effective option. However, numerous concep-
tual and practical problems limit the usefulness of ICERs for decision making.
These problems include, but are not limited to, negative ICERs, one-way sensitivity
analyses, complexity of multiple comparator analyses, and statistical limitations
with ratios. The net benefits approach was developed to address the statistical
limitations of ICERs and is now an accepted methodology used in probabilistic
sensitivity analysis to estimate CE confidence intervals and plot acceptability
curves. However, despite the remaining challenges and limitations the use of ICERs
persists, raising the question: Is it time to eliminate the use of ICERs in the report-
ing of CE analyses? METHODS: We propose expanding the net benefit method to
present deterministic CE analysis results using a net monetary benefit (NMB) chart
or table. ANMB chart is plottedwith the x-axis representing theWTP threshold and
the y-axis representing the NMB. The NMB of each option is a line with the inter-
cept representing the cost and the slope representing the effectiveness across a
specified range of WTP values. The line with the greatest NMB at a given WTP
represents the most cost-effective option at that WTP. The vertical distance be-
tween two lines represents the incremental NMB. Dominance, extended domi-
nance, and the frontier are captured graphically and intuitively. Multiple compar-
ator analyses are simplified and one-way sensitivity analyses are enhanced due to
the elimination of negative ICERs. CONCLUSIONS: A net benefits approach pro-
vides a more intuitive, informative, and useful method to present CE results than
the use of ICERs. Moreover, it has the benefit of facilitating a uniform and consis-
tent approach to presenting the results of deterministic and probabilistic CE anal-
yses.
PRM42
VISUALLY EVALUATING THE MEASUREMENT COMPARABILITY BETWEEN
PAPER-BASED AND ALTERNATE VERSIONS OF ADMINISTRATION OF THE LUNG
FUNCTION QUESTIONNAIRE
Gilligan T1, Nelson L1, McLeod L1, Dalal AA2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline, Durham, NC, USA
In randomized crossover designs, intraclass correlation coefficients (ICCs) are often
used to assess the concordance between scores on different administration ver-
sions of patient-reported outcome (PRO) measures. An ICC and its associated cri-
terion for “adequate” concordance enable analysts to simplify information and
provide researchers with a quick and easy way to interpret analysis output. This
strength of the ICC—its simplicity—may also be a weakness. Analysts may over-
look important information (e.g., biases, outliers) when ICCs are used as the pri-
mary method for assessing concordance. One way to avoid overlooking important
information is to include the evaluation of Bland-Altman plots when assessing
concordance. Bland-Altman plots allow one to visually determine whether two
measures produce similar scores, therefore, supplementing the concordance in-
formation gained from the ICC evaluation. ICCs and Bland-Altman plots comple-
ment each other’s strengths. ICCs provide an efficient and concise estimate to
determine the comparability of versions, while Bland-Altman plots provide a
greater level of detail that incorporates a broader view of the analyzed distribu-
tions. The use of the two methods together provides a more holistic view of con-
cordance. We present Bland-Altman plots and corresponding ICCs under a ran-
domized crossover-design, using the Lung Function Questionnaire, a PRO
instrument originally designed to be administered via paper, and later via three
alternate administration versions (Web, interactive voice response system, and
interview). We provide examples to illustrate instances in which ICCs and Bland-
Altman plots agree and disagree. GSK study number: ADC001HO.
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BIOSIMILARS: DEMONSTRATING SIMILARITY THROUGH EVIDENCE
Kleintjens J1, Dahal D1, Mai JC1, Doyle JJ2
1Quintiles, Hawthorne, NY, USA, 2Columbia University, New York, NY, USA
OBJECTIVES: The differences in the active substance of biosimilars compared to
their originator reference product can cause risks that are unique to biologics,
mainly: immunogenicity, long-term safety risks, and lack of efficacy. These risks
are unknown at the launch of a biosimilar and can lead to unexpected costs for
payers. The aim of this abstract is to describe a methodology for evaluating the
unknown risks of biosimilars. METHODS: A structured literature review revealed
that for many biologics, post-marketing observational studies have been set up to
identify long-term safety and efficacy outcomes. These studies are a useful source
of information to quantify the unknown risks of biosimilars and definemethods of
minimizing those risks. The information required is product- and population-spe-
cific. This information first includes potential safety issues such as immunogenic-
ity (all biologics), serious infections and autoimmune disorders (anti-TNFs, inter-
ferons), and increased mortality and cardiovascular events (epoetin). Second,
information is available on long-term benefits such as clinical outcomes that im-
prove overall survival (e.g. reduced recurrence of malignancies through interferon
use and reduced cardiovascular events through insulin use), reduction in health-
care resource utilization (epoetin, somatropin), and proportion of long-term re-
sponders (figrastim, anti-TNF, somatropin). Finally, observational data can be used
to optimize treatment regimens to achieve maximum treatment benefit (epoetin,
insulin, somatropin). All these data can be used in an economic evaluation where
the unknown risks for biosimilars are quantified through worst- and best-case
scenarios. CONCLUSIONS: Often, payers are attracted to biosimilars that have the
lowest acquisition costs. However, the risks of unknown information for these
biosimilars should be valued against the lower price of these drugs. Observational
data for the originator biologic product can be leveraged to quantify these risks.
This can help determine for which drugs and for which populations the unknown
risks outweigh the reduction in acquisition costs.
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OPTIMUM METHODS FOR PRO TRANSLATION AND LINGUISTIC VALIDATION
METHODOLOGY: ONE BACK TRANSLATION OR TWO?
Furtado T, Anderson H, Griffin A, Wild D
Oxford Outcomes Ltd., Oxford, UK
OBJECTIVES: The translation of PRO measures requires a rigorous procedure, in-
cluding dual forward translations, reconciliation, back translation and review, and
debriefing interviews. The relevance of including blinded back translations has
been widely discussed; however, there has been little discussion around back
translation methods. This research aims to gauge the importance of having two
back translations versus only one.METHODS: Past translation and linguistic vali-
dation projects employing the procedures outlined above were reviewed to com-
pare the methodology of using one back translation versus two. RESULTS: In the
dual-back projects, numerous instances were found in which only one back trans-
lator detected an issue. For example: 1. Simple mistranslations can be revealed by
one translator but not another; e.g. ‘activities at home’ was back translated verba-
tim by one back translator but as ‘household activities’ by another, revealing that
the translated term was too narrow and related only to chores; 2. Similarly, con-
textual mistranslations may become apparent in dual back translations. In one
ePRO script, ‘enter training module’ meant to click through to the next page. One
back translator wrote ‘enter’, while ‘insert’ in the second translation highlighted
that the wrong term had been used in this context; 3. Dual translations are also
useful for elucidating nuances in meaning. In Danish, the phrase ‘bad tempered’
became ‘lose my temper’ in one back translation, allowing the lead translator to
alter the ambiguous translation; 4. Dual meanings in the target language may also
be highlighted, for example in Gujarati ‘hospitalisations’ was correctly back trans-
lated by one translator, but the other translated it as ‘clinic’, showing an ambiguity
in the translation. CONCLUSIONS: The high proportion of issues highlighted by
only one back translator, show the importance of using two blinded back transla-
tors in the translation of PRO measures.
PRM45
PILOT TESTING TRANSLATIONS OF PRO MEASURES WITH SENSITIVE
POPULATIONS
Verjee-Lorenz A, Clayson D, Two R
PharmaQuest Ltd, Banbury, Oxfordshire, UK
The ISPOR Principles of Good Practice paper on the translation of patient-reported
outcome (PRO) measures includes cognitive debriefing as a key step in the trans-
lation process. Cognitive debriefing refers to the process of asking patients to de-
scribe to an interviewer what each question/instruction means to them in their
own words. This allows experienced project managers to then determine whether
the patient has correctly understood the conceptual meaning of the question/
instruction and therefore, by implication, whether the translation is accurate. De-
spite the FDA guidelines emphasising the importance of assessing the content
validity of PRO translations, cognitive debriefing is not always feasible or ethically
acceptable with certain patient groups. These groups include children, severely ill
patients and patients with mental health problems, for whom prolonged inter-
views could cause distress. In these circumstances, alternative methodologies
should be employed to establish whether the wording is suitable for the given
population. Evidence from working with such patients indicates that clinician re-
views, caregiver reviews and assessments of language complexity and suitability
are all useful alternative methods for establishing the acceptability of PRO trans-
lations for particular patient populations. Two examples include pilot testingmen-
tal health measures with clinicians as a substitute for patients experiencing acute
symptoms and pilot testing paediatric measures with health practitioners and
teachers working with children from the target age group. Cognitive debriefing is a
useful tool in the translation and linguistic validation of PROmeasures but a more
flexible approach is required to ensure that certain patients are not unduly dis-
tressed and burdened by the process.
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R . . . YOU AWARE HOW USEFUL IT IS? THE VALUE OF CORRELATION
COEFFICIENTS IN META-ANALYSIS
Al-Dakkak I, Patel S, Jen MH, von Maltzahn R
HERON Evidence Development Ltd, Luton, UK
Meta-analysis involves pooling effect sizes to combine results from studies at-
tempting to answer similar research questions. Typically, a commonmetric is used
to estimate associations between independent and dependent variables in pooled
studies. Nonetheless, studies vary considerably in their measurement of effect
sizes as well as the nature of studied variables. The calculation of an effect size r
allows the pooling of results that are reported in a variety of forms. In the presence
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